JP7353474B2 - Irak阻害剤、その製造方法及び用途 - Google Patents
Irak阻害剤、その製造方法及び用途 Download PDFInfo
- Publication number
- JP7353474B2 JP7353474B2 JP2022519127A JP2022519127A JP7353474B2 JP 7353474 B2 JP7353474 B2 JP 7353474B2 JP 2022519127 A JP2022519127 A JP 2022519127A JP 2022519127 A JP2022519127 A JP 2022519127A JP 7353474 B2 JP7353474 B2 JP 7353474B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- formula
- acid
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910906833 | 2019-09-24 | ||
CN201910906833.7 | 2019-09-24 | ||
PCT/CN2020/117093 WO2021057785A1 (zh) | 2019-09-24 | 2020-09-23 | 一种irak抑制剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022549870A JP2022549870A (ja) | 2022-11-29 |
JP7353474B2 true JP7353474B2 (ja) | 2023-09-29 |
Family
ID=75165579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022519127A Active JP7353474B2 (ja) | 2019-09-24 | 2020-09-23 | Irak阻害剤、その製造方法及び用途 |
Country Status (23)
Country | Link |
---|---|
US (1) | US20220298139A1 (hr) |
EP (1) | EP4015513B1 (hr) |
JP (1) | JP7353474B2 (hr) |
KR (1) | KR20220035450A (hr) |
CN (2) | CN118146193A (hr) |
AU (1) | AU2020352311B2 (hr) |
BR (1) | BR112022001568A2 (hr) |
CA (1) | CA3152167C (hr) |
CL (1) | CL2022000725A1 (hr) |
CO (1) | CO2022004978A2 (hr) |
DO (1) | DOP2022000054A (hr) |
EC (1) | ECSP22032016A (hr) |
ES (1) | ES2967642T3 (hr) |
HR (1) | HRP20240122T8 (hr) |
HU (1) | HUE065288T2 (hr) |
IL (1) | IL291158A (hr) |
LT (1) | LT4015513T (hr) |
MX (1) | MX2022003504A (hr) |
PE (1) | PE20220944A1 (hr) |
PT (1) | PT4015513T (hr) |
TW (1) | TWI832010B (hr) |
WO (1) | WO2021057785A1 (hr) |
ZA (1) | ZA202204441B (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230250064A1 (en) * | 2020-06-23 | 2023-08-10 | Shanghai Meiyue Biotech Development Co., Ltd. | Preparation method for fused pyrazole-type compound |
AU2022239519A1 (en) * | 2021-03-19 | 2023-10-05 | Shanghai Meiyue Biotech Development Co., Ltd. | Polymorphic forms of compound and preparation method therefor and application thereof |
CN114404415A (zh) * | 2022-02-25 | 2022-04-29 | 上海美悦生物科技发展有限公司 | 吲唑类化合物用于治疗银屑病的用途 |
CN115252609B (zh) * | 2022-08-01 | 2023-05-26 | 上海美悦生物科技发展有限公司 | 一种irak4抑制剂的组合物及其制备方法、用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016506367A (ja) | 2012-11-08 | 2016-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
JP2017500326A (ja) | 2013-12-19 | 2017-01-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規なインダゾールカルボキサミド、その調製法、これらを含む医薬製剤および医薬品を製造するためのその使用 |
WO2017108744A1 (de) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
JP2017535585A (ja) | 2014-11-26 | 2017-11-30 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規置換インダゾール、その製造方法、前記新規置換インダゾールを含む医薬製剤、および薬剤を製造するための前記新規置換インダゾールの使用 |
JP2018514539A (ja) | 2015-04-30 | 2018-06-07 | バイエル ファーマ アクチエンゲゼルシャフト | Irak4の阻害剤とbtkの阻害剤の組み合わせ |
WO2019089580A1 (en) | 2017-10-31 | 2019-05-09 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
WO2019133531A1 (en) | 2017-12-26 | 2019-07-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
JP2019520348A (ja) | 2016-06-01 | 2019-07-18 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物におけるアレルギー性および/または炎症性疾患の治療および予防に有用な置換インダゾール |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2067663A1 (en) * | 1991-05-01 | 1992-11-02 | Hitoshi Tone | Pyrazine derivatives |
CN109153665B (zh) * | 2016-03-03 | 2021-10-15 | 拜耳医药股份有限公司 | 新的2-取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
WO2017207385A1 (de) * | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
EP3889150A4 (en) * | 2018-12-25 | 2022-02-23 | Shanghai Meiyue Biotech Development Co., Ltd. | IRAQ INHIBITOR COMPOUND |
CN111499612B (zh) * | 2019-01-30 | 2022-12-30 | 上海美悦生物科技发展有限公司 | 一种作为irak抑制剂的化合物及其制备方法和用途 |
US20230250064A1 (en) * | 2020-06-23 | 2023-08-10 | Shanghai Meiyue Biotech Development Co., Ltd. | Preparation method for fused pyrazole-type compound |
-
2020
- 2020-09-23 PE PE2022000414A patent/PE20220944A1/es unknown
- 2020-09-23 JP JP2022519127A patent/JP7353474B2/ja active Active
- 2020-09-23 LT LTEPPCT/CN2020/117093T patent/LT4015513T/lt unknown
- 2020-09-23 KR KR1020227005043A patent/KR20220035450A/ko unknown
- 2020-09-23 PT PT208699538T patent/PT4015513T/pt unknown
- 2020-09-23 TW TW109132989A patent/TWI832010B/zh active
- 2020-09-23 CN CN202410250421.3A patent/CN118146193A/zh active Pending
- 2020-09-23 HR HRP20240122TT patent/HRP20240122T8/hr unknown
- 2020-09-23 US US17/754,121 patent/US20220298139A1/en active Pending
- 2020-09-23 BR BR112022001568A patent/BR112022001568A2/pt unknown
- 2020-09-23 WO PCT/CN2020/117093 patent/WO2021057785A1/zh active Application Filing
- 2020-09-23 CN CN202080062424.4A patent/CN114391013B/zh active Active
- 2020-09-23 HU HUE20869953A patent/HUE065288T2/hu unknown
- 2020-09-23 AU AU2020352311A patent/AU2020352311B2/en active Active
- 2020-09-23 ES ES20869953T patent/ES2967642T3/es active Active
- 2020-09-23 MX MX2022003504A patent/MX2022003504A/es unknown
- 2020-09-23 CA CA3152167A patent/CA3152167C/en active Active
- 2020-09-23 EP EP20869953.8A patent/EP4015513B1/en active Active
-
2022
- 2022-03-07 IL IL291158A patent/IL291158A/en unknown
- 2022-03-10 DO DO2022000054A patent/DOP2022000054A/es unknown
- 2022-03-23 CL CL2022000725A patent/CL2022000725A1/es unknown
- 2022-04-20 ZA ZA2022/04441A patent/ZA202204441B/en unknown
- 2022-04-20 CO CONC2022/0004978A patent/CO2022004978A2/es unknown
- 2022-04-21 EC ECSENADI202232016A patent/ECSP22032016A/es unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016506367A (ja) | 2012-11-08 | 2016-03-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
JP2017500326A (ja) | 2013-12-19 | 2017-01-05 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規なインダゾールカルボキサミド、その調製法、これらを含む医薬製剤および医薬品を製造するためのその使用 |
JP2017535585A (ja) | 2014-11-26 | 2017-11-30 | バイエル・ファルマ・アクティエンゲゼルシャフト | 新規置換インダゾール、その製造方法、前記新規置換インダゾールを含む医薬製剤、および薬剤を製造するための前記新規置換インダゾールの使用 |
JP2018514539A (ja) | 2015-04-30 | 2018-06-07 | バイエル ファーマ アクチエンゲゼルシャフト | Irak4の阻害剤とbtkの阻害剤の組み合わせ |
WO2017108744A1 (de) | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
JP2019520348A (ja) | 2016-06-01 | 2019-07-18 | バイエル・アニマル・ヘルス・ゲーエムベーハー | 動物におけるアレルギー性および/または炎症性疾患の治療および予防に有用な置換インダゾール |
WO2019089580A1 (en) | 2017-10-31 | 2019-05-09 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
WO2019133531A1 (en) | 2017-12-26 | 2019-07-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Non-Patent Citations (1)
Title |
---|
REGISTRY[online],2011.1.12-2015.7.9, [Retrieved on 2023.3.24], Retrieved from:STN, CAS登録番号1797805-52-7、1259116-59-0 |
Also Published As
Publication number | Publication date |
---|---|
PT4015513T (pt) | 2023-12-19 |
IL291158A (en) | 2022-05-01 |
US20220298139A1 (en) | 2022-09-22 |
JP2022549870A (ja) | 2022-11-29 |
CA3152167C (en) | 2023-12-19 |
HUE065288T2 (hu) | 2024-05-28 |
CL2022000725A1 (es) | 2022-11-18 |
AU2020352311A1 (en) | 2022-04-14 |
ECSP22032016A (es) | 2022-05-31 |
HRP20240122T1 (hr) | 2024-04-12 |
KR20220035450A (ko) | 2022-03-22 |
CN118146193A (zh) | 2024-06-07 |
MX2022003504A (es) | 2022-07-19 |
HRP20240122T8 (hr) | 2024-05-24 |
DOP2022000054A (es) | 2022-07-15 |
PE20220944A1 (es) | 2022-05-31 |
AU2020352311B2 (en) | 2023-11-09 |
EP4015513B1 (en) | 2023-11-01 |
WO2021057785A1 (zh) | 2021-04-01 |
EP4015513A4 (en) | 2022-09-14 |
TWI832010B (zh) | 2024-02-11 |
CN114391013A (zh) | 2022-04-22 |
TW202115015A (zh) | 2021-04-16 |
CO2022004978A2 (es) | 2022-04-29 |
CA3152167A1 (en) | 2021-04-01 |
CN114391013B (zh) | 2024-01-26 |
ZA202204441B (en) | 2022-11-30 |
BR112022001568A2 (pt) | 2022-03-22 |
ES2967642T3 (es) | 2024-05-03 |
LT4015513T (lt) | 2023-12-11 |
EP4015513A1 (en) | 2022-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7353474B2 (ja) | Irak阻害剤、その製造方法及び用途 | |
ES2381895T3 (es) | Inhibidores de PI 3-quinasa y métodos para su uso | |
TWI719209B (zh) | 嘧啶酪氨酸激酶抑制劑 | |
US10336697B2 (en) | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | |
WO2013185082A2 (en) | Inhibitors of bruton's tyrosine kinase | |
JP7491896B2 (ja) | Pde3/pde4二重阻害剤としての融合三環式化合物 | |
ES2973714T3 (es) | Bencimidazoles sustituidos como inhibidores de PAD4 | |
EP4269403A1 (en) | Aromatic heterocyclic compound, and pharmaceutical composition and application thereof | |
TWI671302B (zh) | 具有吲哚胺2,3-雙加氧酶抑制活性的稠合咪唑化合物 | |
JP7086075B2 (ja) | Ccr2/ccr5受容体拮抗剤としてのビフェニル化合物 | |
CN111718332B (zh) | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 | |
WO2023060362A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
EA044151B1 (ru) | Ингибитор irak и способ его получения и применения | |
WO2020143800A1 (zh) | 肝脏特异性ampk激动剂及其制法和应用 | |
CN114790164B (zh) | 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途 | |
WO2022159980A1 (en) | Pharmaceutical compounds and methods of making and using the same | |
TW202333677A (zh) | 蛋白質激酶C θ抑制劑 | |
CN116547277A (zh) | P300抑制剂及其在医药上的应用 | |
CN117186074A (zh) | 哒嗪-3-甲酰胺化合物作为tyk2抑制剂 | |
EP4142874A1 (en) | Pyrimidin-4(3h)-one derivatives as trpv4 antagonists | |
TW202328104A (zh) | 羰基橋連雜環類化合物、及其組合物與應用 | |
CA3194090A1 (en) | Macrocyclic compound | |
CN117186075A (zh) | 取代的哒嗪-3-甲酰胺化合物作为tyk2抑制剂 | |
TW202409011A (zh) | 人類呼吸道融合病毒及間質肺病毒抑制劑 | |
KR20190032534A (ko) | C5a 수용체 길항제로서의 시클릭 펩티드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220323 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230919 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7353474 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |